[CAS NO. 2226735-55-1] GSK'547
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [2226735-55-1]
Catelog
SLK-S8787
Brand
Selleck
CAS
2226735-55-1
DESCRIPTION [2226735-55-1]
Overview
| MDL | MFCD32062767 |
|---|---|
| Molecular Weight | 396.39 |
| Molecular Formula | C20H18F2N6O |
| SMILES | N#CC1=NC=NC(N2CCC(C(N3N=CC[C@H]3C4=CC(F)=CC(F)=C4)=O)CC2)=C1 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5228 mL | 12.6138 mL | 25.2277 mL |
| 5 mM | 0.5046 mL | 2.5228 mL | 5.0455 mL |
| 10 mM | 0.2523 mL | 1.2614 mL | 2.5228 mL |
| 50 mM | 0.0505 mL | 0.2523 mL | 0.5046 mL |
Description
GSK'547 is a highly selective and potent inhibitor of exhibiting a 400-fold improvement in mouse pharmacokinetic oral exposure compared with GSK'963
Targets
| RIP1 [1] |
In vitro
GSK'547 (RIP1i) treatment in vitro directs the programming of bone marrow-derived macrophages (BMDM) toward an immunogenic phenotype, upregulating MHC-II, TNFa, and IFNg, while concomitantly reducing CD206, IL-10, and TGFb expression. Moreover, RIP1i upregulates STAT1 signaling in BMDM, which is associated with M1 programming, but reduced STAT3, STAT5, and STAT6 signaling, which are linked to M2-like macrophage differentiation. Furthermore, RIP1i-treated macrophages display enhanced ability to capture antigen.
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.